Tuesday, July 02, 2019 10:57:50 PM
Nice find, Lima. Thank you.
Note of interest on this “dot”:
From the Eisai G2D2 Tweet description:
“Seeking to deliver tailor-designed cutting-edge medicines
Our precision chemistry strategy - in the context of insights from human genetics - is uniquely positioned to deliver tailor-designed small molecule, anti-sense oligo-nucleotide, and other solutions for targeted therapeutics.”
Note: Small molecule. A2-73 is a small molecule. Of course, not neglecting: precision chemistry based on presumably data from human genetics (mentioned). Sounds familiar.
From this link:
https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0181-2
“Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid ß (Aß) protofibrils.”
BAN2401 is a monoclonal antibody (mab - 100% failure rate in AZ), not a small molecule.
What do we think Eisai thinks their realistic! chances of success for BAN2401 are? (That’s their only “bun in the oven”)
Their current ph 3 trial is not enriched with human genetics which have been mined for precise correlations to specific targets.
So, they turn to this initiative and hop on the “precision train”. But, hey, at least they hopped on! Can not criticize them there! Smart move.
More to ponder. Adds interest to the narrative when taken as a whole.
Thank you for the new find.
As always, wait and see...
(We got this.)
Bio
Note of interest on this “dot”:
From the Eisai G2D2 Tweet description:
“Seeking to deliver tailor-designed cutting-edge medicines
Our precision chemistry strategy - in the context of insights from human genetics - is uniquely positioned to deliver tailor-designed small molecule, anti-sense oligo-nucleotide, and other solutions for targeted therapeutics.”
Note: Small molecule. A2-73 is a small molecule. Of course, not neglecting: precision chemistry based on presumably data from human genetics (mentioned). Sounds familiar.
From this link:
https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0181-2
“Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid ß (Aß) protofibrils.”
BAN2401 is a monoclonal antibody (mab - 100% failure rate in AZ), not a small molecule.
What do we think Eisai thinks their realistic! chances of success for BAN2401 are? (That’s their only “bun in the oven”)
Their current ph 3 trial is not enriched with human genetics which have been mined for precise correlations to specific targets.
So, they turn to this initiative and hop on the “precision train”. But, hey, at least they hopped on! Can not criticize them there! Smart move.
More to ponder. Adds interest to the narrative when taken as a whole.
Thank you for the new find.
As always, wait and see...
(We got this.)
Bio
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
